No Picture
News

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

Designation Underscores Urgent Need for New Antifungals Targeting Multidrug-Resistant Pathogens

SAN DIEGO, Sept. 9, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-… […]

No Picture
News

Precision IBD Announces Next Phase Of Growth: Appoints Mark C. McKenna As President And Chief Executive Officer, Completes Name Change To Prometheus Biosciences, Inc.

Company Plans to Complete Series C Financing in Fourth Quarter of 2019, Followed by Initial Public Offering for 2020

SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — Precision IBD, Inc., a biopharmaceutical company focused on the discovery and development of… […]

No Picture
News

NuVasive Expands Cervical Advanced Materials Science(TM) Portfolio with Launch of Porous Titanium Implant

SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the commercial lau… […]

No Picture
News

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

SAN DIEGO, Sept. 4, 2019 /PRNewswire/ — Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the enrollment of the first patient in a Phase … […]

No Picture
News

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

LOS ANGELES, Sept. 4, 2019 /PRNewswire/ — ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific conferences in September and October… […]

No Picture
News

SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections

– Proprietary conserved antigen with potential to provide broad protection against strains of Group A Strep licensed from University of California San Diego –

FOSTER CITY, Calif., Sept. 3, 2019 /PRNewswire/ — SutroVax, Inc., a biopharmaceutical com… […]

No Picture
News

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached–INBRX-109 demonstrated a PK profile similar to conventional antibodies, providing potential validation of the Inhibrx sdAb platform-

SAN DIEGO, Sept. 3, 2019 /PRNewswire/ — In… […]